Back
4D Molecular Therapeutics, Inc. 10K Form
Sell
47
FDMT
4D Molecular Therapeutics, Inc.
Last Price:
$9.47
Seasonality Move:
-17.45%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2021-03-25 | 10K | FDMT/4D Molecular Therapeutics, Inc. Annual |
Receive FDMT News And Ratings
See the #1 stock for the next 7 days that we like better than FDMT
FDMT Financial Statistics
Sales & Book Value
| Annual Sales: | $85.2M |
|---|---|
| Cash Flow: | $28.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $8.78 |
| Price / Book: | 0.96 |
Profitability
| EPS (TTM): | -2.51460 |
|---|---|
| Net Income (TTM): | $-140.1M |
| Gross Margin: | $77.6M |
| Return on Equity: | -30.78% |
| Return on Assets: | -27.58% |
4D Molecular Therapeutics, Inc. Earnings Forecast
Key 4D Molecular Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 9 years for FDMT is 91.05%.
-
The Selling, General & Administrative Expenses for FDMT have been equal to 57.58% of Gross Profit Margin.
-
The Research & Development expenses have been 229.67% of Revenue.
-
The Net Earning history of FDMT is -164.43% of Total Revenues.
-
Per Share Earnings over the last 9 years have been positive in 3 years.
4D Molecular Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | FDMT |
| CUSIP: | 35104E |
| Website: | 4dmoleculartherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0.04 |
|---|---|
| Current Ratio: | 9.39 |
| Quick Ratio: | 9.15 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
FDMT Technical Analysis vs Fundamental Analysis
Sell
47
4D Molecular Therapeutics, Inc. (FDMT)
is a Sell
Is 4D Molecular Therapeutics, Inc. a Buy or a Sell?
-
4D Molecular Therapeutics, Inc. stock is rated a SellThe current 4D Molecular Therapeutics, Inc. [FDMT] share price is $9.48. The Score for FDMT is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.